Gene Therapy & Gene Editing Deal Benchmarks

Gene therapy and gene editing platforms are attracting transformative licensing deals across oncology and rare disease. Phase 1 gene therapy deals carry a median total deal value of $864M, with upfront payments ranging from $41M to $149M. The high valuations reflect the one-time curative potential and breakthrough therapy designations frequently granted to these approaches.

Development milestones account for $310M in a typical gene therapy deal, reflecting the extensive clinical de-risking required around durability of expression, immunogenicity management, and manufacturing consistency of viral vectors. Regulatory milestones ($272M) and commercial milestones ($194M) complete the value stack.

Royalty rates for gene therapy span 8.5% to 14.9% at the base tier. The unique pricing dynamics of curative one-time therapies -- often priced at $1M+ per patient -- create distinctive commercial milestone structures where sales thresholds must account for small patient populations but high per-patient revenue.